This also provides another rationale for routine NGS of glioma samples (or targeted testing for driver mutations via ddPCR) along with MGMT testing, as mutation data not only refines the histopathologic diagnosis, but also indicates how reliable the MGMT result is likely to be. Here, MGMT is linked to central nervous system cancer.